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ABSTRACT 
The article presents the results of optimization of pharmaceutical care (PC) for children with joint diseases (DJ) in 
conditions of inpatient and outpatient treatment, at the regional level, which allow to improve the quality of PC for 
children with DJ; to rationalize the doctors’ prescriptions; to determine the medicinal budget and to optimize the 
medical supply of children's medical organizations (MO). In addition, the practical significance of the study is in 
improving the quality of medical care in the medical organizations; ensuring the availability of medical care in the 
outpatient settings, by facilitating the selection of a set of drugs, in accordance with the possibilities of the family 
budget; rationalization of labor costs of specialists; ensuring satisfaction of patient with the quality of 
pharmaceutical care; increasing the responsibility of patients parents when using drugs at home, as well as 
ensuring timely reference to specialists; reducing the incidence of patients; reducing the period of staying in the 
conditions of inpatient treatment, etc. 
Keywords: pharmaceutical care, medicinal preparations, joint diseases, children, complex pharmacoeconomic 
research, formulary lists, brand portfolios. 
 
INTRODUCTION  
At present, joint diseases in children, united in 
the group "juvenile arthritis" (JA), have a 
tendency of steady growth in the population of 
children and adolescents, that causes a high 
social and medical significance of the problem. 
The disease often tends to be chronic 
progressive, and it is also the cause of the 
development of childhood disability, which 
occurs during the first 10 years of illness in 50% 
of children with joint damages [1-6].  The 
pharmacotherapy of nosology is sequential. It is 
based on the long-term course of administration 
of a great number of medicinal products (M), 
outpatient and inpatient treatment, and therefore, 
the timeliness and completeness of 
pharmaceutical care is often the one of the 
leading factors in curing of sick child [4,7-10]. 
However, to date, there are some problems in 
providing PC for children with joint diseases in 
the medical organizations: a wide variety of 
medical organizations for treating DJ in the 
pharmaceutical market; difficulties in the choice 
of medicines by doctors for outpatient and 
inpatient treatment; the absence of formulary 
lists and brand portfolios of drugs for treatment 
of DJ in children in the conditions of hospital 
care and outpatient care (HC and PC); 
information deficit of medical and 
pharmaceutical experts in the questions of 
medicinal care for children with DJ, etc. 
The solution of these problems is possible by the 
forming of complex approaches to optimizing 
pharmaceutical care for children with joint 
diseases, based on the system management, 
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pharmacoeconomics, as well as pharmaceutical 
information. 
 
METHODOLOGY 
The methods of logical, system, structural, 
graphic and content-analyzes; the methods of 
strategic management (STEEP- and SWOT-
analysis); economic-mathematical methods 
(grouping, variational statistic, ranking, 
correlation-regression, value); sociological 
methods (expert assessments, questionnaires); 
computer-aided design, are used in the work. 
 
MAIN PART 
At the heart of comprehensive analysis of 
literature sources, the status and problems in 
providing of pharmaceutical care to children 
with joint diseases were studied. It was indicated 
high medical and social significance of juvenile 
arthritis, due to the increase in the incidence rate 
among the children's population of the Russian 
Federation, the tendency to chronic progressive 
course and the risk of early disability. It has 
been established, that the pharmacotherapy of 
children with this pathology is complex and 
involves the use of significant assortment of 
medicines, long-term, expensive treatment and 
rehabilitation. However, to date, having a large 
number of proposals of the pharmaceutical 
market, medical specialists are suffered from 
information deficit in the process of  medicines 
prescription for the treatment of children with 
joint diseases in the conditions of hospital care 
and outpatient care; and pharmaceutical 
specialists have a lack of information in the field 
of pharmaceutical counseling. This is largely 
due to the lack of restrictive lists of medicines 
for treatment children with joint diseases. The 
solution of these problems is possible by the 
forming of complex approaches to optimization 
of PC for children with DJ, based on system 
management, pharmacoeconomics, as well as 
pharmaceutical information. The system of 
studies, aimed at optimizing pharmaceutical care 
for children with joint diseases has been 
developed, in order to provide an integrated 
approach to the solving of problems, on the 
basis of system analysis and targeted modeling. 
The research system includes 3 blocks (Figure 
1). The analysis of PC potential for children 
with joint diseases (based on the example of the 
Belgorod region) was carried out within the 
framework of the first block, in accordance with 
the developed research system. It includes 6 
stages: pharmaceutical care analysis from the 
position of system management; the analysis of 
the macro-environment factors, affecting the 
pharmaceutical care of children; the analysis of 
the micro-environment factors, affecting the PC 
of children with joint diseases; the audit of the 
HC and PC internal environment in the field of 
pharmaceutical care for children with joint 
diseases; comprehensive assessment of macro- 
and microenvironment factors through the 
implementation of SWOT-analysis and 
compilation the matrix of opportunities and 
threats; definition of complex measures for 
optimization of pharmaceutical care for children 
with DJ in the region. In the analysis of 
pharmaceutical care from the position of system 
management, the main participants were 
identified: parents, doctors and pharmaceutical 
workers. In the framework of the macro-
environment analysis, the socio-economic 
characteristic of the Belgorod Region was given; 
STEEP-analysis of environmental factors was 
carried out. The impact of environmental factors 
was estimated as average. In the course of the 
evaluation of microenvironment factors, 
marketing analysis of Russian and regional 
pharmaceutical markets of medicinal 
preparations for the treatment of DJ in children 
was carried out. So, in particular, the 
macrocontour of the Russian market of 
preparations for juvenile arthritis treatment 
includes 5 groups, according to the АТC-
classification, 620 preparations, 14 international 
non-proprietary names (INN), 25 trade names 
(TN) of preparations. In this structure, anti-
inflammatory and antirheumatic medicines are 
leading (89.0%), among them the leading 
position is occupied by acetic acid derivatives 
(92.8%), monocomponent composition (97.0%). 
Domestic medicinal preparations are dominated 
on the basis of production (60.0%), the 
company-manufacturer is “Ozon”, LLC 
(25.0%).  
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Solid pharmaceutical forms (50.7%), in 
particular, enteric-coated tablets (65.0%) are 
dominated in the structure of assortment.  
 
 
 
Figure 1 - Structural-logical scheme of the research 
system on optimizing pharmaceutical care for 
children with joint diseases 
 
The average index of the assortment renewal is 
45.0%. The meso-contour of the regional 
pharmaceutical market of the Belgorod region 
was determined. It was established, that it 
entered the boundaries of the macrocontour, was 
similar in its parameters to the main parameters, 
and used the opportunities of the Russian market 
by 87.5%. 
At the next stage, the sociological study of the 
services consumer - a child with joint disease - 
was carried out. Medico-social portraits of 
children with juvenile arthritis - patients of 
children's hospitals - were developed. So, in 
particular, the hospital patient is a boy (53.7%); 
at the age of 12 to 18 (35.6%); resident of the 
region (69.0%); living in a full family (78.0%); 
sent to a hospital from consultative polyclinic 
(66.2%); with clinical diagnosis "reactive 
arthritis" (63.8%); who was treated for an 
average of 14.5 days; having concomitant 
disease cardiopathy (33.6%). 
In sociological survey of 60 parents of children 
with a joint diseases, the main consumer criteria 
for choosing medicines were identified, in the 
process of pharmacotherapy of children with 
joint diseases in outpatient settings: high 
pharmacotherapeutic efficacy (61.2%), safety 
(22.4%), price (7.5%), and easiness of use - 
dosage form (DF) and the frequency of 
admission (6%). 
The next stage was a comprehensive SWOT-
analysis. It has been established, that the PC 
potential for children with DJs in the Belgorod 
region is currently under moderate favorable 
conditions, which is largely due to the indirect 
influence of stress factors of the external 
environment. Among the main threats to the 
development of pharmaceutical care for children 
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with joint diseases are the following: the 
difficulty of choosing of medicinal preparations 
by the inpatient and outpatient doctors, due to 
the lack of  information for prescribing drugs, 
the absence of restrictive lists of medicinal 
preparations for the treatment of juvenile 
arthritis in medical organizations, the lack of 
interaction in the system: "pharmacist-patient 
(patient’s parent)"; the lack of preventive 
materials for children, etc. In order to solve the 
identified problems, the "Optimization Program 
of Pharmaceutical Care for Children with Joint 
Diseases in the Belgorod Region for 2016-2017" 
was developed. It includes 7 vectors of action: 
the rationalization of legal framework for the 
provision of pharmaceutical care for children 
with joint diseases; optimization of 
pharmacological support for children's medical 
organizations; improvement of pharmaceutical 
information on prescription of medicines, etc. 
The methodical approach for a comprehensive 
pharmacoeconomic research of medicinal care 
for children, simultaneously in the outpatient 
and inpatient settings, was developed for the 
first time, aimed at the implementation of the 
second block of the research system. 
The advantages of this approach are the 
following: the possibility of studying the 
sequence and succession of treatment; 
identification of tendencies in the process of 
formation of medicines assortment and 
performance of comparative analysis; 
optimization the expert examination of drugs, 
due to a clear delineation of requirements for 
pharmacotherapy, depending on the conditions 
of medical care; and, as a consequence, the 
formation of the most rational restrictive lists of 
medicinal preparations. 
The methodological approach provides for the 
simultaneous and consistent implementation and 
comparative analysis of the research stages: the 
formation of the information base of medicinal 
preparations; structural analysis of medicines 
assortment; АВС-analysis of medicines 
assortment; multifaceted expertise of 
assortment; formation of the restrictive lists of 
medicines for the treatment of children in 
outpatient and inpatient settings; normative and 
cost analysis and determination of the medicinal 
budget of the hospital department. 
Within the framework of methodical approach, 
the technology for carrying out a multifaceted 
expertise of the medicines assortment was 
developed for the first time. It includes multi-
stage sequential evaluation of the medicines 
assortment, conducted by pharmaceutical and 
medical specialists, according to a great number 
of criteria. The technology of multifaceted 
expertise of medicines assortment helps to 
optimize the selection of drugs in restrictive lists 
and provides for the implementation of the 
following actions: pharmaceutical evaluation of 
medicines from the position of their 
characteristics, VEN-expertise, analysis of 
conformity to consumer preferences, evaluation 
of cost criteria. 
At the first stage, pharmaceutical expertise (PE) 
of the medicinal preparations is implemented by 
highly competent pharmaceutical specialists (the 
representatives of the MO formulary 
committee). Pharmaceutical expertise includes: 
the analysis of medicines assortment 
characteristics; the selection of medicinal 
preparations, which maximally meet the 
requirements of the expertise; elimination of 
drugs, which have limitations to the 
prescription; and formation of summary 
analytical information about the assortment, 
with the purpose of medical experts training, for 
carrying out the subsequent VEN-expertise. 
The technology of pharmaceutical expertise 
includes sequential execution of the following 
stages: determination of criteria for 
pharmaceutical expertise of medicinal 
preparations assortment for specific conditions 
of the analysis; the analysis of the list of 
medicinal preparations characteristics, selection 
and justification of the choice of their use under 
specific research conditions; identification of 
barrier (restrictive) characteristics of medicines; 
removal from the expertise such medicines, 
which do not fully comply with the criteria; 
creation of information materials on the 
characteristics of medicinal preparations, for 
optimization of VEN-expertise of the medicines 
assortment by doctors. At the second stage, 
VEN-expertise of the medicines assortment is 
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carried out by highly qualified specialists in 
order to segment the assortment of medicines, 
according to the criteria optimality: 
"pharmacotherapeutic efficiency" - "safety", to 
justify inclusion of medicines in restrictive lists. 
The goal of the third stage is to analyze the 
medicines assortment for compliance with 
consumer preferences, that means an assessment 
of the correspondence of medicinal preparations 
characteristics to consumer criteria, identified 
during the sociological survey of services 
consumers. At the fourth and final stage, the 
cost criteria are evaluated by comparing the cost 
of medicinal preparations and the cost of 
treatment (according to the results of the ABC-
analysis). 
Methodical approach was applied in the course 
of comprehensive pharmacoeconomic study of 
medicinal care for children with juvenile 
arthritis in outpatient and inpatient settings of 
children's hospitals in the Belgorod region. 
At the initial stage of the study, it was conducted 
the content analysis of 900 case histories of 
children with juvenile arthritis - the patients of 
hospitals, and 86 outpatient cards - the patients 
of polyclinics. In the course of the analysis, two 
types of juvenile arthritis were diagnosed: 
juvenile chronic arthritis (JCA) and reactive 
arthritis (RA). As a result, further research in the 
inpatient setting was carried out for these 
nosological forms of juvenile arthritis. 
An information array of was formed. It included 
72 TN, 48 MNN, 2575 packages of 
pharmaceutical drugs for outpatient institutions, 
and 106 TN, 78 MNN and 1565 packages of 
drugs for hospitals. 
The structure of the assortment and consumption 
of drugs for the treatment of these nosologies 
were defined. They are mainly formed from 6 
groups, according to the ATC-classification. 
Among them the following are dominated: 
"Remedies, affecting the digestive system and 
metabolism"; "Remedies, affecting the 
musculoskeletal system"; "Hormones of 
systemic action", etc. 
Further, the analysis was made for the 
compliance of the outpatient assortment with 
consumer characteristics. With the help of 
medical experts, inconsistencies in the use of 
medicines for pharmacotherapeutic efficacy 
(25.7%); security (67%); easiness of application 
(37.7%) were defined. The analysis for the 
criterion "affordable price" showed, that every 
third prescribed drug is expensive. Then, with 
the help of the ABC-analysis, the medicines 
assortment was segmented according to the 
frequency of prescription and the costs for the 
treatment course. Thus, it was found out, that in 
the inpatient setting, the high consumption 
group "A" for the treatment of juvenile arthritis 
occupied 22.05% of the total assortment 
volume. It was formed with preparations, having 
the range of assignment coefficient (Ca) from 
17.4 to 2.3 and included 15 preparations - 
Diclofenac, Meloksikam, Metipred, 
Sulfasalazine, etc. The average consumption 
group "B" (22%) consisted of 15 medicinal 
preparations with a range of Ca from 2.1 to 0.3 - 
Diprospan, Voltaren, Methotrexate, etc. Low 
consumption group "C" (54,4%) included 38 
preparations with Ca from 0.3 and lower - 
Nexium, Movalis, Indomethacin, and others. 
At the next stage, the technology of multifaceted 
examination of the medicines assortment was 
used for the first time. At the first stage, the 
inpatient and outpatient assortment was 
analyzed in detail - 80 and 72 M for the 
treatment of juvenile arthritis, respectively, from 
the position of their characteristics. For the 
examination, 19 M characteristics were defined, 
while only 57% were reflected in the 
"Instructions for use". 
In the course of the analysis, in particular, it was 
found that more than 90% of all medicines do 
not have a child dosage and only 30% of them 
have the possibility of dividing, with 
minimizing the risk to the child's body. Only 6% 
of drugs have a children's dosage form. It was 
revealed, that 67% of medicines from outpatient 
assortment were prescribed. According to the 
results of pharmaceutical expertise, about 20% 
of medicines were removed from the assortment, 
having restrictions for use. Analytical 
information materials on the characteristics of 
preparations of the selected assortment, for the 
training of medical experts, for conducting 
VEN- expertise were also formed. 
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At the next stage, the VEN-expertise was carried 
out, for the purpose of segmenting the medicines 
for the treatment of juvenile arthritis, according 
to the rate of clinical relevance, economic 
feasibility and compliance with consumer 
criteria. 47 highly qualified doctors-experts, the 
specialists of children's hospitals and polyclinics 
of Belgorod, Kursk and other cities of Russia, 
took part in the examination. The average 
coefficient of expert competence was 0.85. 
Based on the average weighted values, the 
assortment of medicines was divided into main 
medicines (V), important, or substitute drugs (E) 
and non-essential (impractical) (N) drugs. So, in 
particular, the group "V" includes 20 
preparations: Movalis (tablets), Voltaren 
(solution for injection), etc.; the group "E" 
includes 21 preparations: Dolgit (gel), 
Diprospan (solution for injection) and others; 
the group "N" includes - 36 drugs: Magnesium 
orotate (tablets), Metamizol sodium (solution for 
injection), etc. 
At the final stage, 5 preliminary formulary lists 
of medicinal preparations have been developed 
for the treatment of children with RA, associated 
by urogenital, enterogenic and nasopharyngeal 
infections; polyarticular and oligoarticular 
arthritis in the inpatient setting. Three brand 
portfolios of medicines for the treatment of 
children with juvenile poly-/ oligoarticular 
arthritis in outpatient settings - high-cost 
("Comfort"); medium-cost ("Standard") and 
low-cost ("Economy") for a course of 1 month 
treatment. 
The fourth and final block of the study is 
devoted to the formation of pharmaceutical 
informational and methodological materials for 
all participants of the PC: methodical 
recommendations on optimization of 
pharmaceutical counseling by drugstores, about 
the preparations for treatment of joint diseases in 
children; methodical recommendations on the 
rationalization of prescriptions and the choice of 
medicines by doctors for the treatment of a child 
with a joint diseases in a hospital and polyclinic; 
pharmacoeconomic maps and 
pharmacotherapeutic stands for parents of 
children with joint diseases, providing the 
possibility of self-selection of medicines 
complex, based on its price availability; 
valeological video materials for informing 
children about the problem of joint diseases. 
 
CONCLUSION 
The significance of the study is to develop 
methodological approaches to the complex 
pharmacoeconomic study of medicinal care for 
children, in the conditions of outpatient and 
inpatient treatment; the technologies of 
multifaceted expertise of preparations 
assortment, with participation of pharmaceutical 
experts and doctors. 
 
DEDUCTIONS 
1. The system of studies on optimization of PC 
for children with DJ has been applied; 
2. Marketing analysis of the Russian and 
regional pharmaceutical markets of preparations, 
for the treatment of DJ in children was carried 
out; 
3. Sociological study of schoolchildren in 
Belgorod, parents of children with DJ, 
pediatricians and children's rheumatologists was 
performed; 
4. Comprehensive pharmacoeconomic study of 
medicinal care for children with juvenile 
arthritis has been implemented; 
5. Preliminary formulary lists of preparations for 
the treatment of juvenile arthritis in hospitals 
and brand portfolios of drugs for the treatment 
of juvenile arthritis in outpatient settings were 
formed; 
6. Pharmaceutical information-methodological 
materials for participants of PC (pharmaceutical 
workers, doctors-specialists, parents and 
children with joint diseases) were developed. 
 
REFERENCES 
1. Atlanta G.A., 2016. Juvenile Arthritis. 
Arthritis Foundation. Mode of access: 
http://www.arthritis.org/about-
arthritis/types/juvenile-arthritis. 
2. Baranov A.A., Nasonov E. L., Alekseeva 
E.I. 2007. The state of specialized 
rheumatological care for children and 
adults in the Russian Federation: the project 
of the Federal target program "Rheumatic 
diseases, 2008-2012": according to the 
Optimization of Pharmaceutical Care for Children with Joint Diseases 
 
Irina V. Spichak, et al.                                                                                                               1034 
report materials at the presidium meeting of 
RAMS, January 17, 2007. Issues of modern 
pediatrics. Vol. 6, №1. - Pp. 6-8. 
3. Beukelman T., Patkar N. M., Saag K. G., 
2011. American College of Rheumatology 
recommendations for the treatment of 
juvenile idiopathic arthritis: initiation and 
safety monitoring of therapeutic agents, for 
the treatment of arthritis and systemic 
features. Arthritis Care Re. Vol. 63, № 4. – 
Pp. 465-482. 
4. Hashkes P. J., Laxer R. M., 2005. Medical 
treatment of juvenile idiopathic arthritis. 
JAMA. Vol. 294, № 13. – Pp. 1671-1684.  
5. Kahn P., 2009. Juvenile idiopathic arthritis – 
current and future therapies. Bull. NYU 
Hosp. Jt. Dis. Vol. 67, № 3. – Pp. 291-302. 
6. Krivova V.N., Savvateeva V.G., 
Kadesnikova T.A., 2009. Childhood 
disability: clinical examination and 
rehabilitation in the conditions of a 
polyclinic: textbook for students of the 6th 
year, 39 p. 
7. Nasonov E. L., Nasonova V.A., 2008. 
Rheumatology. National Manual, 414 p. 
8. Ruperto N., Ravelli A., Castell E., 2006. 
Cyclosporine A in juvenile idiopathic 
arthritis. Results of the PRCSG/PRINTO 
phase IV, post marketing surveillance study 
[Text] /[et al.]// Clin. Exp. Rheumatol., 
Vol. 24, № 5. – Pp. 599-605. 
9. Spichak I.V., Dereglazova Y.S., 2011. 
Marketing research of the medicines market 
for the treatment of juvenile arthritis // 
Belgorod State University Scientific 
bulletin. Ser. Medicine. Pharmacy. №15. - 
Pp. 251-254. 
10. Spichak I.V.,Dereglazova Y. S., 
Petrovskaya T.Y., 2016. Analysis of the 
bsu pharmacy’s assortment of medicines 
for the treatment of juvenile arthritis. 
"Research results". Online Journal. 
Medicine and Pharmacy Series, Vol.2, № 2. 
Рp. 62-65. 
 
